Cabaletta Bio, Inc.
CABA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001759138
No open-market purchases or sales by Cabaletta Bio, Inc. insiders were filed in the last 90 days; 139 institutions reported holding it in 13F filings for Q2 2026, worth $490.4M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Cabaletta Bio, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 72 | 84 | +12 |
| Shares | 24.6M | 36.4M | +11.8M (+47.9%) |
| Value | $203.9M | $470.5M | +$266.6M (+130.8%) |
New holders (29)
Institutions that held Cabaletta Bio, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (17)
Institutions that held Cabaletta Bio, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 265,355 | $2.19M |
| Goldman Sachs Group Inc | 161,596 | $1.34M |
| Jane Street Group, LLC | 103,791 | $858.4K |
| HRT Financial LP | 100,224 | $828.0K |
| Caxton Corp | 40,581 | $335.6K |
| Cubist Systematic Strategies, LLC | 36,457 | $301.5K |
| Citadel Advisors LLC | 21,197 | $175.3K |
| 683 Capital Management, LLC | 17,000 | $140.6K |
| Concorde Asset Management, LLC | 15,800 | $130.7K |
| LMR Partners LLP | 13,422 | $111.0K |
| Man Group plc | – | $109.5K |
| Boothbay Fund Management, LLC | 12,528 | $103.6K |
| Diametric Capital, LP | 10,966 | $90.7K |
| Trexquant Investment LP | 10,511 | $86.9K |
| Point72 Asset Management, L.P. | 5,243 | $43.4K |
| Point72 Middle East FZE | 3,742 | $30.9K |
| Denali Advisors LLC | 1,400 | $11.6K |